Cargando…

The viral vector vaccine VSV-GP boosts immune response upon repeated applications

Detalles Bibliográficos
Autores principales:	Tober, R, Banki, Z, Ejaz, A, Muik, A, Egerer, L, von Laer, D, Kimpel, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441870/ http://dx.doi.org/10.1186/1742-4690-9-S2-P301

Ejemplares similares

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer
por: Schreiber, Liesa-Marie, et al.
Publicado: (2019)

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
por: Wilmschen, Sarah, et al.
Publicado: (2019)

Optimizing expression of functional HIV envelopes in rVSV-ΔG vaccine vectors
por: Wright, KJ, et al.
Publicado: (2012)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
por: Dambra, Richard, et al.
Publicado: (2022)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

Development and Applications of VSV Vectors Based on Cell Tropism
por: Tani, Hideki, et al.
Publicado: (2012)

Human Transcriptomic Response to the VSV-Vectored Ebola Vaccine
por: Santoro, Francesco, et al.
Publicado: (2021)

Evaluation of a replication-competent VSV-SIV vaccine candidate
por: Jurgens, CK, et al.
Publicado: (2012)

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
por: Vijver, Saskia V., et al.
Publicado: (2023)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Safety of Recombinant VSV–Ebola Virus Vaccine Vector in Pigs
por: de Wit, Emmie, et al.
Publicado: (2015)

Analyses of Entry Mechanisms of Novel Emerging Viruses Using Pseudotype VSV System
por: Tani, Hideki
Publicado: (2014)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
por: Spearman, P, et al.
Publicado: (2012)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

Bioreactor production of rVSV‐based vectors in Vero cell suspension cultures
por: Kiesslich, Sascha, et al.
Publicado: (2021)

Targeting Viral Antigens to CD11c on Dendritic Cells Induces Retrovirus-Specific T Cell Responses
por: Ejaz, Asim, et al.
Publicado: (2012)

P19-02. High protection of female macaques from repeated intravaginal challenges with SHIV-162P3 upon mucosal vaccination with Gp41 subunits-virosomes
por: Bomsel, M, et al.
Publicado: (2009)

P18-09. Persistent virological benefit in SIV-infected macaques upon therapeutic vaccination upon vaccination with DNA vectors
por: Felber, BK, et al.
Publicado: (2009)

Spray dried VSV-vectored vaccine is thermally stable and immunologically active in vivo
por: Toniolo, Steven P., et al.
Publicado: (2020)

Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV
por: Wilmschen, Sarah, et al.
Publicado: (2019)

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum
por: Pipperger, Lisa, et al.
Publicado: (2019)

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
por: Bánki, Zoltán, et al.
Publicado: (2022)

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
por: Rössler, Annika, et al.
Publicado: (2023)

Chemogenetic ON and OFF switches for RNA virus replication
por: Heilmann, E., et al.
Publicado: (2021)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
por: Qiu, Xiangguo, et al.
Publicado: (2009)

P19-37. Replication-defective lymphocytic choriomeningitis virus vectors boost cellular and humoral immunity after DNA or adenovirus vector priming
por: Flatz, LR, et al.
Publicado: (2009)

Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect
por: Hofer, Tamara, et al.
Publicado: (2021)

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
por: Jelinski, Joseph, et al.
Publicado: (2023)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

E-DNA IM or ID delivery prime enhances antibody and T cell responses following recombinant gp120 env boost
por: Hutnick, NA, et al.
Publicado: (2012)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3r8aq7p8es9jv5shd1kh16lad6